Danny Palnoch appointed CHE Honorary Fellow
Posted on Wednesday 18 November 2026
Danny Palnoch has been appointed as an Honorary Fellow at the Centre for Health Economics (CHE), University of York, bringing experience in medicines policy, pharmaceutical economics and NHS decision-making.
Danny is Head of Medicines Analysis within Medicines Value and Access at NHS England, where he leads a team of around 25 analysts supporting work across medicines procurement and supply chain, medicines negotiations, managed access and medicines policy.
A career spanning nearly four decades
Danny has worked as a government economist for nearly 40 years. After short periods in the Northern Ireland Civil Service and Customs and Excise, he joined the Department of Health and Social Care (DHSC) in 1991.
He initially worked on social care funding and local authority grant allocations before moving into NHS specialised services. He then spent 25 years working on pharmaceutical issues, including 10 years as a senior civil servant at DHSC, before joining NHS England in early 2018.
Throughout his career, Danny has developed specialist expertise in the economics of the pharmaceutical industry, branded medicines pricing and regulation, health technology assessment principles, community pharmacy reimbursement and remuneration, and generics pricing.
Supporting medicines policy and decision-making
In his current role at NHS England, Danny oversees a team whose work supports decision-making across the medicines landscape.
His work covers a wide range of areas, including:
- Antimicrobial resistance: Developing evaluation and payment models for antimicrobial products that encourage the development of new treatments while maintaining conservation goals.
- NICE methods: Advising on the implications of potential changes to NICE methods.
- Commercial policy: Providing advice on commercial strategy, including approaches such as indication-specific pricing.
- Horizon scanning: Assessing the future medicines landscape, including new treatments and the loss of exclusivity for existing products.
- Medicines expenditure: Monitoring NHS medicines spending and supporting short- and longer-term forecasting, including the implications of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).
- Medicines optimisation: Providing analysis to support policies aimed at improving outcomes and value across the NHS.